肝移植治疗胆管细胞癌。
Liver Transplant for Cholangiocarcinoma.
机构信息
Division of Transplantation Surgery, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA.
Division of Transplantation Surgery, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA.
出版信息
Gastroenterol Clin North Am. 2018 Jun;47(2):267-280. doi: 10.1016/j.gtc.2018.01.002.
Liver transplant (LT) for perihilar cholangiocarcinoma (CCA) offers an opportunity for survival among patients with early-stage but anatomically unresectable disease. The 5-year survival rate after LT is 65% to 70%, higher among patients with primary sclerosing cholangitis, who are often diagnosed earlier, and lower among patients with de novo CCA. The results of LT for hilar CCA, along with recent limited data suggesting favorable survival among patients with very early intrahepatic CCA (ICC), have reignited interest in the subject. This article discusses LT following neoadjuvant therapy for CCA and the early data on LT alone for ICC.
肝移植（LT）治疗肝门部胆管癌（CCA）为早期但解剖上不可切除疾病的患者提供了生存机会。LT 后的 5 年生存率为 65%至 70%，在原发性硬化性胆管炎患者中更高，这些患者通常更早被诊断出来，而在新诊断的 CCA 患者中更低。LT 治疗肝门部 CCA 的结果，以及最近表明非常早期肝内 CCA（ICC）患者生存良好的有限数据，重新引起了人们对这一主题的兴趣。本文讨论了 CCA 新辅助治疗后的 LT 以及单独用于 ICC 的早期 LT 数据。
Zotero 插件